Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC

Qiu, Bin; Guo, Wei; Zhang, Fan; Lv, Fang; Ji, Ying; Peng, Yue; Chen, Xiaoxi; Bao, Hua; Xu, Yang; Shao, Yang; Tan, Fengwei; Xue, Qi; Gao, Shugeng; He, Jie

doi:10.1038/s41467-021-27022-z

Cited by 138 publications

(167 citation statements)

References 41 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…It is a rare report to examine the importance of cfDNA on a practical clinical level and the first to do so in an Asian cohort. The superiority of ctDNA detection even in a small number of cases and the fact that similar results have been obtained for other cancer types suggests that ctDNA may be superior to existing diagnostic imaging methods 34 . To address these limitations, we believe that we can expect to gain more insight into ctDNA by studying a higher number of cases, extending the observation period, and increasing the number of oncogene search items.…”

Section: Discussionsupporting

confidence: 56%

Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma

Chikuie

Urabe

Ueda

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Early recurrence detection of head and neck squamous cell carcinoma (HNSCC) is important for improving prognosis. Recently, circulating tumor DNA (ctDNA) has been reported to be useful in early detection or treatment response determination in various carcinomas. This study aimed to identify the utility of ctDNA for predicting recurrent metastasis in patients with HNSCC. We collected pre-treatment tissues (malignant and normal tissues) and multiple plasma samples before and after treatment for 20 cases of HNSCC treated with radical therapy. ctDNA was detected in pre-treatment plasma in 10 cases; however, there were no significant associations with tumor recurrence and staging. During follow-up, ctDNA was detected in 5 of the 7 plasma samples of recurrent cases but not in the 13 recurrence-free cases. Moreover, there was a significant difference in post-treatment relapse-free survival time between the groups with and without detected ctDNA (20.6 ± 7.7 vs. 9.6 ± 9.1 months, respectively; log-rank test, p < 0.01). Moreover, for two of the five cases with ctDNA detected after treatment, ctDNA detection was a more sensitive predictor of recurrence than imaging studies. ctDNA detection during treatment follow-up was useful in patients with HNSCC for predicting the response to treatment and recurrent metastasis.

show abstract

Section: Discussionsupporting

confidence: 56%

Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma

Chikuie

Urabe

Ueda

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…From a clinical perspective, the assessment of variants in ctDNA can provide valuable information complementary to tissue sequencing and offer new opportunities for the prediction of the response to targeted therapy and the monitoring of disease recurrence, but also for diagnosis and prognosis [ 23 ], as summarized in Figure 1 .…”

Section: Introductionmentioning

confidence: 99%

Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer

et al. 2022

View full text Add to dashboard Cite

The concept of liquid biopsy as an analysis tool for non-solid tissue carried out for the purpose of providing information about solid tumors was introduced approximately 20 years ago. Additional to the detection of circulating tumor cells (CTCs), the liquid biopsy approach quickly included the analysis of circulating tumor DNA (ctDNA) and other tumor-derived markers such as circulating cell-free RNA or extracellular vesicles. Liquid biopsy is a non-invasive technique for detecting multiple cancer-associated biomarkers that is easy to obtain and can reflect the characteristics of the entire tumor mass. Currently, ctDNA is the key component of the liquid biopsy approach from the point of view of the prognosis assessment, prediction, and monitoring of the treatment of non-small-cell lung cancer (NSCLC) patients. ctDNA in NSCLC patients carries variants or rearrangements that drive carcinogenesis, such as those in EGFR, KRAS, ALK, or ROS1. Due to advances in pharmacology, these variants are the subject of targeted therapy. Therefore, the detection of these variants has gained attention in clinical medicine. Recently, methods based on qPCR (ddPCR, BEAMing) and next-generation sequencing (NGS) are the most effective approaches for ctDNA analysis. This review addresses various aspects of the use of liquid biopsy with an emphasis on ctDNA as a biomarker in NSCLC patients.

show abstract

“…In the last few years, together with biomarker analysis performed on tissue samples, circulating tumour DNA has been investigated to better understand the molecular behaviour of NSCLC [49]. The early assessment of this relevant marker can predict recurrence in early-stage and locally advanced NSCLC, which could lead to the prompt start of specific targeted therapies [50].…”

Section: Discussionmentioning

confidence: 99%

Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review

Gallina

Bertolaccini

Forcella

et al. 2022

Cancers

View full text Add to dashboard Cite

Next-generation sequencing has become a cornerstone in clinical oncology practice and is recommended for the appropriate use of tailored therapies in NSCLC. While NGS has already been standardised in advanced-stage NSCLC, its use is still uncommon in the early stages. The recent approval of Osimertinib for resected EGFR-mutated NSCLC in an adjuvant setting has launched the hypothesis that other targeted therapies used in metastatic patients can also lead to improved early-stage outcomes of NSCLC. The impact of molecular biomarkers on the prognosis of patients undergoing radical surgery for NSCLC is still unclear. Notably, the heterogeneous populations included in the studies that analysed surgical patients could be the main reason for these results. In this review, we report the most important studies that analysed the impact of principal molecular biomarkers on the survival outcomes of patients who underwent radical surgery for NSCLC.

show abstract

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC

Cited by 138 publications

References 41 publications

Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma

Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma

Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer

Analysis of Molecular Biomarkers in Resected Early-Stage Non-Small Cells Lung Cancer: A Narrative Review

Contact Info

Product

Resources

About